来地帕韦与替诺福韦在HIV-HCV共感染患者中的药物相互作用:对替诺福韦谷浓度及肾脏安全性的影响
该研究纳入26例接受替诺福韦方案并治疗来地帕韦/索磷布韦的HIV-HCV共感染患者,评估来地帕韦对替诺福韦血浆谷浓度和估算肾小球滤过率的影响。结果显示替诺福韦谷浓度从基线78 ng/ml升至1个月141 ng/ml(P=0.003),但肾功能指标无显著变化,提示来地帕韦通过抑制P-糖蛋白增加替诺福韦暴露,但未对肾功能造成显著影响。
要点
- 来地帕韦可使替诺福韦谷浓度显著升高,临床应关注替诺福韦暴露增加。
- 在肾功能正常或轻度损害患者中,未观察到估算肾小球滤过率显著下降。
- 3例患者在治疗结束后12周从慢性肾脏病1期进展至2期,需监测肾功能。
核心结论
- 来地帕韦通过抑制P-糖蛋白显著增加替诺福韦暴露,但在肾功能正常或轻度损害人群中未对肾小球滤过功能产生显著影响。
研究设计与样本
- 研究纳入26例接受替诺福韦方案抗逆转录病毒治疗并接受来地帕韦/索磷布韦治疗的HIV-HCV共感染患者,评估替诺福韦血浆谷浓度和估算肾小球滤过率的变化。
主要发现
- 替诺福韦谷浓度(四分位距)从基线78 ng/ml(53-110)升至1个月141 ng/ml(72-176),P=0.003。
- Cockcroft-Gault公式估算的肾小球滤过率中位数(四分位距)在基线、1个月、治疗结束和治疗结束后12周分别为101.3 ml/min(91.1-114.1)、102.4 ml/min(89.8-112.9,P=0.26)、96.5 ml/min(82.4-115.4,P=0.39)和100.5 ml/min(83.3-111.9,P=0.24)。
- MDRD公式估算的肾小球滤过率中位数(四分位距)在基线、1个月、治疗结束和治疗结束后12周分别为95.6 ml/min(86.5-111.2)、92.5 ml/min(88.1-114.3,P=0.27)、95.4 ml/min(84.2-105.4,P=0.16)和93.4 ml/min(82.2-103.5,P=0.16)。
- 3例患者在治疗结束后12周从慢性肾脏病1期进展至2期。
临床怎么用
- 对于接受替诺福韦方案的HIV-HCV共感染患者,合用来地帕韦/索磷布韦时应关注替诺福韦暴露增加,并监测肾功能。
局限性
- 研究样本量较小(26例),且患者肾功能正常或仅轻度损害,结论外推至中重度肾功能损害患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluate the impact of ledipasvir on both tenofovir plasma trough concentration and estimated glomerular renal function in human immunodeficiency virus-hepatitis C virus coinfected patients receiving a tenofovir-based antiretroviral regimen and treated with ledipasvir/sofosbuvir. Twenty-six patients [81% male, median age: 51 years; hepatitis C virus genotype 1(75%)/4(15%)] were included. Tenofovir trough concentration (interquartile range) increased from 78 ng ml-1 (53-110) at baseline to 141 ng ml-1 (72-176) at 1 month (P = 0.003). No significant difference on estimated glomerular renal function using both Cockroft-Gault and Modification of Diet in Renal Disease formulae, respectively, [median (interquartile range)] was observed between baseline [101.3 ml min-1 (91.1-114.1); 95.6 ml min-1 (86.5-111.2)], 1 month [102.4 ml min-1 (89.8-112.9), P = 0.26; 92.5 ml min-1 (88.1-114.3), P = 0.27], end-of-treatment [96.5 ml min-1 (82.4-115.4), P = 0.39; 95.4 ml min-1 (84.2-105.4), P = 0.16] and 12 weeks after the end of treatment [100.5 ml min-1 (83.3-111.9), P = 0.24; 93.4 ml min-1 (82.2-103.5), P = 0.16]. Three patients progressed from chronic kidney disease stage 1 to stage 2 at 12 weeks post-treatment. A significant increase in tenofovir exposure through P-glycoprotein inhibition by ledipasvir was confirmed without significant impact on glomerular renal function in our population with normal renal function or mild renal impairment.
引用
- Solas C, Bregigeon S, Faucher-Zaegel O, et al. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety. Br J Clin Pharmacol. 2017. PMID: 29028125. doi:10.1111/bcp.13450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。